Intelligence for what comes next.
AI-enabled, decision-ready competitive intelligence from a pharma-insider team. We help biopharma CI and brand leaders anticipate competitor moves, avoid strategic blind spots and make decisions that stay relevant from development through commercialization.
A pharma-insider CI team, built by former brand and CI leaders
AdametNext is a biopharma competitive intelligence firm. We work as an extension of your CI and brand teams, connecting scientific, clinical, regulatory and commercial signals into one view you can act on.
Founded in 2019 by Virendra Kumar after a career leading CI and brand insights at Bayer, GSK and Novartis. Headquartered in Hyderabad, with teams in the US, UK and Singapore.
Pharma-native judgement
Former brand managers and CI leads interpret every signal in its clinical and commercial context.
Connected evidence
Secondary, primary and congress intelligence, triangulated and confidence-rated.
Governed AI delivery
Three proprietary AI platforms add speed and consistency. Our analysts own every conclusion.
Competitive futures are shaped long before launch
Competitor decisions surface in secondary data 12–24 months after they are made.* By then, the window to respond has narrowed. We help you see those shifts at every stage of the asset.
Where is the science going?
Which assets are accelerating?
What will define differentiation?
How might the regulatory bar shift?
What will sustain standard of care?
What is changing?
What could it mean for our asset?
What should we prepare for now?
We answer all three questions, so leaders anticipate competitive change and make decisions that stay relevant from development through commercialization.
*AdametNext analysis of the lag between competitor decisions and IQVIA data, press releases, publications and abstracts.
Three intelligence engines, one decision-ready view
Organized around your KITs and KIQs, not a fixed information feed. We run the full CI cycle, from the annual plan to the tools that run it.
See all CI services →Secondary CI
Maintain strategic visibility
- Competitor, clinical and regulatory monitoring
- Alerts, trackers and forward watchpoints
- Landscapes, earnings and IR analysis
Primary CI
Test the critical unknowns
- Expert, KOL and stakeholder interviews
- Hypothesis testing and triangulation
- Confidence-rated view of competitor intent
Conference Intelligence
Capture inflection points
- 20+ congresses: ASCO, ESMO, ASH, ESC, ATS
- Pre-congress KIT/KIQ planning
- Daily highlights and strategic debrief
Depth across seven core therapy areas
Our analysts bring hands-on experience from the brands and pipelines they have supported, not just the databases they have searched.
From one founder’s conviction to a trusted CI partner
Built to raise the quality of pharma CI, bringing the inside-out perspective of a former brand and CI leader to every engagement.
AdametNext is founded
Virendra Kumar starts ADN after a decade of client-side CI and brand roles at Bayer, GSK and Novartis.
Clients, preferred vendor
Three global top-20 pharma companies, US biotechs and specialty pharma, across primary and secondary CI.
Specialists, four countries
Hyderabad HQ and Delhi, Short Hills NJ, London and Singapore, plus freelance consultants across EU4, Canada, UAE and Australia.
AI-led CI, community-led growth
Three proprietary AI platforms. SAMANVAY brings together India’s pharma GCC community, and ADN exhibits at Pharma CI USA.
Future readiness at scale
SAMANVAY 2027, deeper AI-enabled CI and new therapy-area franchises.
Global coverage, delivered from Hyderabad’s pharma GCC hub
Onshore consultants across major pharma markets, backed by our offshore delivery centre. A hybrid model that works around the clock.
Toronto
Short Hills, NJ
London
EU4
Dubai
Delhi
Hyderabad (HQ)
Singapore
BrisbaneHyderabad, India
An emerging pharma GCC capital
New pharma GCCs, 2024–26: Eli Lilly · Amgen · BMS · MSD · Regeneron · Lonza
Led by people who have sat in your seat
“We don’t just tell you what competitors are doing. We help you understand what it means for your business, and prepare for what comes next.”
Virendra Kumar · Founder & CEO
16+ years in pharma CI and brand insights · ex-Novartis Global CI Lead, Respiratory · Supported Ultibro, Enerzair & Atectura Breezhaler and Xolair PFS launches
AI speeds the work. Analysts own every conclusion.
Three proprietary platforms power our engagements: AI-enabled, human-validated and client-controlled.
Explore the platforms →
CI plans, KITs/KIQs, governed workflows, alerts and Ask CI search, with continuity across teams and years.
Coverage planning, live capture, task delegation and AI-enabled session insights, inside your secured IT environment.
Curated signals across companies, assets and trials, turned into company-specific implications for your portfolio.
Trusted by global pharma, biotech and specialty companies
3 global top-20 pharma companies, US biotechs, and specialty and biosimilar leaders, across therapy areas and indications.
More client voices →The shared insights were spot-on.
The attention to detail in finding business implications was commendable.
Frameworks from our foresight practice
White papers, articles and a book on how CI teams can protect value and influence decisions.
All thought leadership →Follow AdametNext on LinkedIn
CI frameworks, congress takeaways, events and team news, in your feed every week.
